|Title:||Use of inhibitors of the renin-angiotensin system|
|Abstract:|| It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.|
|Inventor(s):|| Montgomery; Hugh Edward (London, GB), Martin; John Francis (London, GB), Erusalimsky; Jorge Daniel (London, GB) |
|Assignee:|| Ark Therapeutics Limited (GB) |
|Filing Date:||Jul 26, 2002|
|Claims:||1. A method for the treatment of cancer cachexia, wherein said method comprises administering to a person or animal in need of such treatment a lipophilic inhibitor of the renin-angiotensin system; and wherein the inhibitor of the rennin-angiotensin system is an inhibitor of angiotensin-coverting enzyme ("ACE"). |
2. The method, according to claim 1, wherein the ACE inhibitor is selected from the group consisting of quinapril, captopril, lisinopril, peridopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril lisinopril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, cilazapril, delapril, enalaprilat, fosinopril, moveltiprqil and trandolapril.